热门资讯> 正文

Kiora Pharmaceuticals GAAP每股收益为-0.54美元

2025-08-08 19:09

Kiora Pharmaceuticals press release (NASDAQ:KPRX): Q2 GAAP EPS of -$0.54.
Ended the quarter with $20.7 million in cash, cash equivalents and short-term investments, along with $2.4 million in collaboration receivables and $0.7 million in research incentive tax credits.
Maintained projected cash runway into late 2027, a timeframe beyond anticipated data readouts for KLARITY and ABACUS-2, with potential for further extension through achievement of partnership milestones.

More on Kiora Pharmaceuticals

Kiora Pharmaceuticals granted U.S. patent expanding protection for KIO-104 for treatment of ocular disease
Seeking Alpha’s Quant Rating on Kiora Pharmaceuticals
Historical earnings data for Kiora Pharmaceuticals
Financial information for Kiora Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。